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Sampling and Need for Re-Biopsy 
Background 
Assessing expression of PD-L1 on tumour cell membranes by immunochemistry is an important 
complementary or crucial companion diagnostic test to guide the use of immune modulating 
checkpoint inhibitors in the treatment of non-small cell lung cancer (NSCLC).¹ Unfortunately, the 
known temporal and spatial heterogeneity of PD-L1 expression raises the important question of how 
to ensure that the small biopsy specimens with which this assessment is usually made are 
adequately representative of PD-L1 expression by the whole tumour.² 
Method 
Expression of PD-L1 was assessed in sections of 65 tissue blocks from 20 primary pulmonary 
adenocarcinomas and 20 primary pulmonary squamous cell carcinomas using the Ventana SP263 
antibody and a validated protocol. Scoring was performed by two appropriately-trained pathologists 
with extensive experience in its interpretation. After conventional assessment, slides were digitally 
scanned and divided into squares of 1mm² area to form a digital database (mean of 150 data-points 
per tumour), which were assigned co-ordinates and re-scored. By these means, multiple, “digital 
core biopsies” (Figure 1) approximating a 17 gauge needle were simulated in sequential fashion, and 


























































<1 14 2 2 6 2 2 Y 
1-10 13 6 1 5 1 0 Y 
11-49 10 1 0 1 0 0 Y 
50-100 13 0 0 0 0 0 n/a 
All 50 18% 6% 3% 0.75% 2 (4%)  
PD-L1, programmed death ligand 1; DCBx, Digital Core Biopsy 
*Based on pembrolizumab categories as: 1st line ≥50%, 2nd line 1-49%; nivolumab categories as: 
≥1% (for adenocarcinoma)  
 
Fig 1. NSCLC overlaid with 1mm² grid and examples of “digital biopsies” 
3 separate “digital biopsies” (these simulate half a 17G core)from a small area of tumour which 
illustrates how position of biopsy even in a 2D space can potentially change PD-L1 TPS %. This error is  
notably increased with focal positivity and low PD-L1 TPS tumours.  
Conclusion 
In the majority of cases, three digital core biopsies achieved closest correlation with the whole 
tumour, with little greater accuracy achieved by assessing four cores or more. Correlation was 
weakest when expression was low and very focal, an important consideration in view of the 
importance of the ‘1% cut-off’ used commonly to guide immune checkpoint therapy.³ Using this 
model as a guide, a single good quality biopsy (2x10mm² area) is sufficient for most tumours scoring 
11% or greater PD-L1 expression. However, in the lower range of expression, re-biopsy might be 
routinely considered if there is doubt about specimen adequacy. 
References 
1. Büttner et al.: Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of 
Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer. J Clin Oncol. 
2017 Dec 1;35(34):3867-3876 
2. Ilie et al.: Comparative study of the PD-L1 status between surgically resected specimens 
and matched biopsies of NSCLC patients reveal major discordances: a potential issue for 
anti-PD-L1 therapeutic strategies. Ann Oncol. 2016 Jan;27(1):147-53. 
3. Hisrch et al.: PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of 
the Blueprint PD-L1 IHC Assay Comparison Project J Thorac Oncol. 2017 Feb;12(2):208-222. 
 
 
